

European Heart Journal

Volume 44 No. 3 January 2023

ISSUE @ A GLANCE



Management of atrial fibrillation: role of population screening, biomarkers, and polygenic risk scores
F. Crea

167

CardioPulse

Preprints: a game changer in scientific publications?

F. Alfonso and F. Crea

171

Meet Habib Gamra: new *European Heart Journal* co-editor for North Africa

J. Ozkan

174

The '10 commandments' for the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

J. Tfelt-Hansen, B.G. Winkel, M. de Riva, and K. Zeppenfeld

176

Weekly Journal Scan

Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges

M. Volpe and C. Patrono

178

FOCUS ISSUE ON ARRHYTHMIAS

META-ANALYSIS

Association between basic life support and survival in sports-related sudden cardiac arrest: a meta-analysis

L. Michelland, M.H. Murad, W. Bougouin, M. Van Der Broek, L.J. Prokop, S. Anys, M.-C. Perier, A. Cariou, J.P. Empana, E. Marijon, X. Jouven, and P. Jabre

180

Editorial

Shocking insights on resuscitation after sports-related cardiac arrest

D. Corrado, A. Cipriani, and A. Zorzi

193

CLINICAL RESEARCH



Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study

J. Lyth, E. Svennberg, L. Bernfort, M. Aronsson, V. Frykman, F. Al-Khalili, L. Friberg, M. Rosenqvist, J. Engdahl, and L.-Å. Levin

196

Editorial

Screening for atrial fibrillation to prevent stroke: increasing enthusiasm but outcomes still lag

E.S. Spatz and J. Herrin

205



Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Z. Hijazi, A.P. Benz, J. Lindbäck, J.H. Alexander, S.J. Connolly, J.W. Eikelboom, C.B. Granger, P. Kastner, R.D. Lopes, A. Ziegler, J. Oldgren, A. Siegbahn, and L. Wallentin

208

Editorial

A specific new biomarker for atrial fibrillation and its sequelae?

M.F. Sinner and A.S. von Falkenhausen

219



A polygenic risk score predicts atrial fibrillation in cardiovascular disease

N.A. Marston, A.C. Garfinkel, F.K. Kamanu, G.M. Melloni, C. Roselli, P. Jarolim, D.D. Berg, D.L. Bhatt, M.P. Bonaca, C.P. Cannon, R.P. Giugliano, M.L. O'Donoghue, I. Raz, B.M. Scirica, E. Braunwald, D.A. Morrow, P.T. Ellnor, S.A. Lubitz, M.S. Sabatine, and C.T. Ruff

221

Editorial

Genomic risk scores, biomolecules, and clinical conditions to predict atrial fibrillation: time to integrate what we can measure

S. Käb, H. Holm, and P. Kirchhof

232



DISCUSSION FORUM

Are there other factors that influence the assessment of bleeding risk comparing potent P2Y₁₂ inhibitors with clopidogrel?

C. Xie, Y. Zhang, and J. Lin

235

Oral P2Y₁₂ inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot

M. Galli, L. Ortega-Paz, and D.J. Angiolillo

236

CARDIOVASCULAR FLASHLIGHT

First in man: sealing the distal re-entry tears of aortic dissection after thoracic endovascular aortic repair by an ENDOPATCH™ system

L. Cao, H. Zhang, and W. Guo

237

Cardiac tamponade caused by intrapericardial diaphragmatic hernia

Y.-M. Gu and L.-Q. Chen

238

Filippo



This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

Cardio



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>

oup.com

Sudden

it happens

the cost

port and

a meta-

Cite in r

of basic

in a syste

from the

conducte

three sci

stander

related in

Survival

The me

The

space

for

His

starrin

enth

of we

aid to

tion

Ales

Pad

ally m

that

show

Super

reac

the

the

the

the



www.eurheartj.org